AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Nolato B

Earnings Release Feb 7, 2022

2950_10-k_2022-02-07_035c4ffd-cec6-4064-a70b-1e81fc900319.pdf

Earnings Release

Open in Viewer

Opens in native device viewer

YEAR-END REPORT 2021 January - December

Strong growth in sales and profit

Fourth quarter of 2021 in brief

  • Sales increased to SEK 3,146 million (2,487)
  • Operating profit (EBITA) rose to SEK 336 million (283)
  • EBITA margin of 10.7% (11.4)
  • Profit after tax was SEK 271 million (211), excluding non-recurring items*
  • Diluted earnings per share increased to SEK 1.01 (0.79), excl. non-recurring items
  • Cash flow after investments amounted to SEK −87 million (211)

Full year 2021 in brief

  • Sales increased to SEK 11,610 million (9,359)
  • Operating profit (EBITA) rose to SEK 1,369 million (1,066)
  • Diluted earnings per share were SEK 3.70 (3.12), excl. non-recurring items
  • Cash flow after investments was SEK 446 million (SEK 905 million excl. acquisitions)
  • The equity/assets ratio was 47% (44) and net financial liabilities were SEK 51 million (298)
  • The Board proposes a dividend of SEK 1.90 (1.60) per share

* Net financial income and expense include positive non-recurring items of SEK 115 million, which arose from the revaluation of contingent consideration concerning the acquisition of GW Plastics. See pages 4 and 5 for more details on non-recurring items.

Comments from the President and CEO - well positioned

for continued profitable growth

Adjusted for currency, consolidated sales grew by a considerable 28% to SEK 3,146 million in the fourth quarter, due mainly to very strong growth in Integrated Solutions. Both the quarter and the entire financial year saw constantly fluctuating business conditions, and we have focused on meeting customer needs, managing the effects of the pandemic and ensuring the safety of our employees and cooperation partners. These key priorities, however, resulted in higher costs and relatively lower production efficiency. Consolidated operating profit, measured as EBITA, for the fourth quarter was SEK 336 million, with a margin of 10.7%.

Christer Wahlquist, President and CEO, Nolato AB

Medical Solutions sales for the fourth quarter totaled SEK 1,063 million (951), corresponding to organic growth of 11%. Most areas have seen good demand, although effects from the pandemic are still resulting in postponed surgical operations and lower deliveries of surgical products. Operating profit (EBITA) amounted to SEK 112 million (112), corresponding to a margin of 10.5% (11.8). The margin has been negatively affected both by the ramp-up of a new large project with an existing customer, which temporarily resulted in higher costs in the second half of the year, and by a shortage of materials and labor.

Integrated Solutions sales totaled SEK 1,476 million (907), corresponding to organic growth of a remarkable 67%. The continued robust growth in volumes is due to high demand for vaporiser heating products (VHP), as well as strong EMC performance as a result of the rapid 5G roll-out and new electrification and online connection solutions that are generating business opportunities. Nolato believes that this business area's sales for the first quarter of 2022 will be in line with the fourth quarter of 2021. Operating profit (EBITA) was a strong SEK 192 million (111), with a margin of 13.0% (12.2).

Industrial Solutions sales totaled SEK 609 million (629), corresponding to negative organic growth of 3%. The decrease was due to supply chain disruptions, particularly in the automotive segment. Operating profit (EBITA) totaled SEK 38 million (62), with a margin of 6.2% (9.9). The margin was adversely affected by lower volumes and low production efficiency.

Overall, despite a number of operating environment challenges, we can look back on another year of strong growth in sales and profit, as well as the advancement of our market positions. We have good financial flexibility and are investing in further expansion, both organically and through acquisitions when the time is right, to further bolster our global offering. In other words, we are well positioned for continued profitable growth and to deliver an attractive return for our shareholders.

The Board intends to propose to the AGM a dividend of SEK 1.90 per share (1.60), which corresponds to a pay-out ratio, excluding non-recurring items, of 51%, and a dividend yield of 1.8% on the share price as of December 31, 2021.

Q4 Q4 Full year Full year
SEK million unless otherwise specified Note 2021 2020 2021 2020
Net sales 1 3,146 2,487 11,610 9,359
Operating profit (EBITDA) 449 389 1,805 1,456
Operating profit (EBITA) 336 283 1,369 1,066
EBITA margin, % 10.7 11.4 11.8 11.4
Operating profit (EBIT) 2 326 274 1,333 1,048
Profit after financial income and expense 2 433 269 1,401 1,014
Profit after tax 386 211 1,160 806
Basic earnings per share, SEK 3 1.43 0.79 4.32 3.03
Diluted earnings per share, SEK 3 1.43 0.79 4.32 3.02
Basic adjusted earnings per share, SEK 3 1.46 0.82 4.43 3.08
Diluted adjusted earnings per share, SEK 3 1.46 0.81 4.42 3.08
Cash flow after investments, excluding acquisitions and disposals – 87 211 446 905
Net investments affecting cash flow, excluding acquisitions and disposals 205 102 782 347
Cash conversion, % 35 87
Return on capital employed, % 22.8 20.7
Return on shareholders' equity, % 28.0 23.9
Equity/assets ratio, % 47 44
Net financial liabilities, excluding pension- & lease liabilities – 51 – 298

Group highlights

See definitions of IFRS measures and alternative performance measures on page 22.

Including a non-recurring item of SEK 50 million in operating profit for the full year 2021 and SEK 115 million in profit after financial items in Q4-2021 and full year 2021, which in total impacted the profit after tax by SEK 165 million.

Including a non-recurring item of SEK −31 million in operating profit for full year 2020 and tax effects of SEK +6 million, which impacted profit after tax by SEK −25 million.

This document is a translation from Swedish. In the event of any difference between this version and the Swedish original, the latter shall prevail.

Fourth quarter 2021

  • Sales totaled SEK 3,146 million (2,487), adjusted for currency, which was a considerable 28% increase
  • Strong growth for Medical and Integrated, while Industrial is being affected by supply chain disruptions
  • Operating profit (EBITA) rose to SEK 336 million (283)
  • EBITA margin of 10.7% (11.4) Sales
  • Cash flow after investments totaled SEK −87 million (211) because of increased working capital requirements and a higher level of investment

Sales

Consolidated sales totaled SEK 3,146 million (2,487). This was a considerable 28% increase adjusted for currency.

Medical Solutions sales amounted to SEK 1,063 million (951); adjusted for currency, sales increased by 11%. Growth has been good in most areas. The surgery segment also showed some growth, but continues to be affected by the pandemic in the form of postponed operations.

Integrated Solutions sales totaled SEK 1,476 million (907). Adjusted for currency, this was an increase of a remarkable 67%, driven by strong growth in volumes of vaporiser heating products (VHP), as well as healthy EMC growth. Nolato believes that this business area's sales for the first quarter of 2022 will be in line with the fourth quarter of 2021.

Industrial Solutions sales amounted to SEK 609 million (629); adjusted for currency, sales decreased by 3%. Supply chain disruptions have had an effect, resulting in lower volumes, particularly in automotive.

Strong growth for Medical and Integrated while Industrial is being affected by supply disruptions

• Operating profit (EBITA)

• EBITA margin

The Group's operating profit (EBITA) rose to SEK 336 million (283).

Operating profit (EBITA) was unchanged for Medical Solutions at SEK 112 million (112), while for Integrated Solutions it rose sharply to SEK 192 million (111), and for Industrial Solutions it decreased to SEK 38 million (62).

The EBITA margin for Medical Solutions was 10.5% (11.8). High costs for the start-up of a new project have had a negative impact on the margin. The ramp-up relates to a large project with an existing, globally leading customer in a new area for Nolato with this customer; in vitro diagnostics (IVD). This resulted in disruptions and temporarily higher costs in the second half of the year. A shortage of materials and labor are leading to lower efficiency in Nolato's production, which has further affected the margin compared with the same period of the previous year. For Integrated Solutions, the margin was 13.0% (12.2). A general subsidy of just over SEK 10 million has been received from Chinese authorities, which boosted the margin by 0.8 percentage points. The EBITA margin for Industrial Solutions was 6.2% (9.9). Supply chain disruptions, leading to lower volumes and resulting in lower production efficiency, adversely affected the margin. Overall, the Group's EBITA margin was 10.7% (11.4).

Operating profit (EBIT) was SEK 326 million (274).

Operating profit after net financial income and expense rose to SEK 318 million (269), excluding non-recurring items. Including non-recurring items, profit amounted to SEK 433 million (269). Net financial income and expense include positive non-recurring items of SEK 115 million, which arose from the revaluation of contingent consideration concerning the acquisition of GW Plastics.

Profit after tax was SEK 271 million (211), excluding non-recurring items. Including non-recurring items, profit amounted to SEK 386 million (211). Diluted earnings per share were SEK 1.01 (0.79), excluding non-recurring items. Including non-recurring items, earnings per share amounted to SEK 1.43 (0.79). Adjusted earnings per share after dilution but excluding amortization of intangible assets arising from acquisitions amounted to SEK 1.04 (0.81), excluding non-recurring items.

Profit • Adjusted diluted earnings per share

Sales Sales EBITA EBITA EBITA marg. EBITA marg.
SEK million Q4/2021 Q4/2020 Q4/2021 Q4/2020 Q4/2021 Q4/2020
Medical Solutions 1,063 951 112 112 10.5% 11.8%
Integrated Solutions 1,476 907 192 111 13.0% 12.2%
Industrial Solutions 609 629 38 62 6.2% 9.9%
Intra-Group adj., Parent Co – 2 – 6 – 2
Group total 3,146 2,487 336 283 10.7% 11.4%

Sales, operating profit (EBITA) and EBITA margin by business area

Operating profit (EBITA): Earnings before financial income and expense, taxes and amortization of intangible assets arising from acquisitions.

Full year 2021

Consolidated sales totaled SEK 11,610 million (9,359). This was a significant 18% increase, adjusted for currency and acquisitions.

Sales for Medical Solutions rose by 32% to SEK 4,067 million (3,089), for Integrated Solutions by 28% to SEK 5,226 million (4,068) and for Industrial Solutions by 5% to SEK 2,324 million (2,205).

The Group's operating profit (EBITA) increased to SEK 1,319 million (1,097), excluding non-recurring items. Including non-recurring items, profit amounted to SEK 1,369 million (1,066). Overall, the Group's EBITA margin was 11.4% (11.7%) excluding non-recurring items. Profit for the year includes a positive non-recurring item of SEK 50 million, which relates to a remitted loan. In the previous year, there were non-recurring expenses of SEK −14 million for the closure of a UK business and acquisition expenses of SEK −17 million. These non-recurring items were recognized at Group level and have consequently not affected the profit of the business areas.

Operating profit (EBIT) rose to SEK 1,283 million (1,079), excluding nonrecurring items. Including non-recurring items, profit amounted to SEK 1,333 million (1,048).

Operating profit after net financial income and expense was SEK 1,236 million (1,045), excluding non-recurring items. Including non-recurring items, profit amounted to SEK 1,401 million (1,014).

Profit after tax amounted to SEK 995 million (831), excluding nonrecurring items. Including non-recurring items, profit amounted to SEK 1,160 million (806). Diluted earnings per share rose to SEK 3.70 (SEK 3.12), excluding non-recurring items. Including non-recurring items, diluted earnings per share were SEK 4.32 (3.02). Adjusted earnings per share after dilution, but excluding amortization of intangible assets arising from acquisitions, amounted to SEK 3.81 (3.17), excluding non-recurring items. The effective tax rate was 17.2% (20.5). Excluding non-recurring items, the tax rate was 19.5%.

The return on capital employed was 22.8% (20.7). Return on equity was 28.0% (23.9). Cash conversion was 35% (87).

50%

Medical Solutions •

Sales and profit full year (SEK million) 2021 2020
Sales 4,067 3,089
Operating profit (EBITA) 457 402
EBITA margin (%) 11.2 13.0
Operating profit (EBIT) 430 391

Medical Solutions sales totaled SEK 4,067 million (3,089); adjusted for currency and acquisitions, sales grew by 6%. The year generally saw strong demand in most areas, but mainly in diagnostics, in part because of the pandemic. Growth in the diagnostics segment has, however, been limited by available capacity during certain periods. In addition, volumes in this business area continued to be adversely affected by postponed surgical operations, while there has also been a return to more normal inventory levels by several customers in other areas as pandemic-related restrictions were eased or removed in the third quarter. Growth was good in most areas in the fourth quarter, with the surgical segment also showing some growth, but this area continues to be affected by the pandemic situation as a result of postponed operations.

Operating profit (EBITA) increased to SEK 457 million (402).

The EBITA margin was 11.2% (13.0). A lower operating margin in the acquired US business, consolidated since September 1, 2020, is having a dilutive effect. In addition, the margin was adversely affected by volumes from the third quarter and high costs for the ramp-up of a large project. The ramp-up is resulting in disruptions and temporarily higher costs from the third quarter. A shortage of materials and labor are leading to lower efficiency in Nolato's production, which further affected the margin in the fourth quarter.

Medical Solutions sales

• Medical Solutions operating profit (EBITA) & EBITA margin %

Integrated Solutions

Sales and profit full year (SEK million)
Sales 5,226 4,068
Operating profit (EBITA) 671 548
EBITA margin (%) 12.8 13.5
Operating profit (EBIT) 670 546

Integrated Solutions sales totaled SEK 5,226 million (4,068). Adjusted for currency, sales increased by a remarkable 36% on the back of strong growth in both vaporiser heating products (VHP) and EMC. VHP volumes demonstrated good growth in 2021 and were very high in the third and fourth quarters. EMC sales increased sharply as a result of good growth in telecom and, above all, owing to strong relative growth in automotive. Nolato believes that this business area's sales for the first quarter of 2022 will be in line with the fourth quarter of 2021.

Operating profit (EBITA) was SEK 671 million (548).

The EBITA margin was 12.8% (13.5). The margin has mainly been affected by changes in the sales mix.

2021 2020 Integrated Solutions sales

• Integrated Solutions operating profit (EBITA) & EBITA margin %

Industrial Solutions •

Sales and profit full year (SEK million) 2021 2020
Sales 2,324 2,205
Operating profit (EBITA) 208 168
EBITA margin (%) 9.0 7.6
Operating profit (EBIT) 200 163

Industrial Solutions sales totaled SEK 2,324 million (2,205); adjusted for currency and acquisitions, sales grew by 4%. In 2020, demand from automotive industry customers was significantly impacted by production halts for periods of the year. 2021 was also affected by supply chain disruptions, which impacted volumes. Supply chain disruptions have intensified since the summer vacation period, with component shortages causing some customers to halt production or reduce production capacity periodically.

Operating profit (EBITA) increased sharply to SEK 208 million (168).

The EBITA margin rose to 9.0% (7.6), driven by improved efficiency, especially in the first quarter of the year. The margin was adversely affected in the second half of the year by supply chain disruptions, leading to lower volumes and low production efficiency.

Industrial Solutions sales

• Industrial Solutions operating profit (EBITA) & EBITA margin %

Cash flow •

Cash flow after investments in the fourth quarter was SEK –87 million (SEK 211 million excluding acquisitions and related foreign exchange effects on cash flow). This was supported by the increase in profit, while working capital requirements rose due to higher sales and an increase in committed stock to prevent any disruptions to deliveries. Net investments affecting cash flow rose to SEK 205 million (102).

For the full year 2021, cash flow after investments was SEK 446 million (SEK 905 million excluding acquisitions and related foreign exchange effects on cash flow). Including acquisitions in the previous year, cash flow after investments was SEK 446 million (–531). On an accumulated basis, net investments affecting cash flow increased to SEK 782 million (SEK 347 million excluding acquisitions). Investments mainly relate to the expansion of production capacity. Including acquisitions in the previous year, investments affecting cash flow totaled SEK 782 million (1,695). Cash conversion for the last 12 months was 35% (87). A dividend totaling SEK 428 million (0) was paid to shareholders in the second quarter.

Cash flow after investments

Interest-bearing assets amounted to SEK 1,448 million (1,487) and interestbearing financial liabilities decreased to SEK 1,499 million (1,785). Net financial liabilities consequently totaled SEK 51 million (298). Positive cash flow from the last 12 months has improved net financial liabilities. There are also interest-bearing pension liabilities of SEK 247 million (274) and interestbearing lease liabilities of SEK 295 million (358). Shareholders' equity rose to SEK 4,768 million (3,699). The equity/assets ratio was 47% (44). Nolato has long-term credit agreements amounting to just over SEK 1.5 billion.

Financial position • Net financial liabilities & equity/assets ratio %

Financial position

SEK million 31/12/2021 31/12/2020
Interest-bearing liabilities, credit institutions – 1,499 – 1,785
Cash and bank 1,448 1,487
Net financial liabilities – 51 – 298
Interest-bearing pension liabilities – 247 – 274
Net financial liabilities, including pension liabilities – 298 – 572
Lease liabilities – 295 – 358
Net financial liabilities, including pension- & lease liabilities – 593 – 930
Working capital 480 388
As a percentage of sales (average) (%) 3.7 3.6
Capital employed 6,809 6,116
Return on capital employed (average) (%) 22.8 20.7
Shareholders' equity 4,768 3,699
Return on shareholders' equity (average) (%) 28.0 23.9

Consolidated performance analysis

Q4 Q4 Full year Full year
SEK million Note 2021 2020 2021 2020
Net sales 1 3,146 2,487 11,610 9,359
Gross profit excluding depreciation/amortization 582 523 2,250 1,893
As a percentage of net sales 18.5 21.0 19.4 20.2
Costs – 133 – 134 – 445 – 437
As a percentage of net sales 4.2 5.4 3.8 4.7
Operating profit (EBITDA) 449 389 1,805 1,456
As a percentage of net sales 14.3 15.6 15.5 15.6
Depreciation and amortization – 113 – 106 – 436 – 390
Operating profit (EBITA) 336 283 1,369 1,066
As a percentage of net sales 10.7 11.4 11.8 11.4
Amortization of intangible assets arising from acquisitions – 10 – 9 – 36 – 18
Operating profit (EBIT) 2 326 274 1,333 1,048
Financial income and expense 2 107 – 5 68 – 34
Profit after financial income and expense 2 433 269 1,401 1,014
Tax – 47 – 58 – 241 – 208
As a percent of profit after financial income and expense 10.9 21.6 17.2 20.5
Profit after tax 386 211 1,160 806

Personnel • Contact:

The average number of employees during the period was 8,669 people (6,721). The increase in the number of employees is mainly attributable to Integrated Solutions' operations in China and the acquisition in the US.

Significant risks and uncertainty factors

The Group and parent company's business risks and risk management, as well as the management of financial risks, are described on pages 53–55 and in Note 30 on pages 83–86 of the 2020 annual accounts.

No events of material significance occurred in the period that materially affect or change these descriptions of the Group and parent company's risks and their management.

Seasonal effects

Nolato does not experience any significant seasonal variations. However, in the third quarter sales within Industrial Solutions and, to a certain degree, Medical Solutions can be negatively affected by the fact that the vacation period falls in this quarter both for Nolato and its customers.

Events after the balance sheet date

No significant events have occurred since the end of the period, but, owing to Covid-19, Nolato is operating in an environment that, at the time of this report's publication, is still affecting the Group in various ways.

  • Christer Wahlquist, President and CEO, tel. +46705 804848.
  • Per-Ola Holmström, CFO, tel. +46705 763340.

• Webcast conference call on 7 February:

In connection with the year-end report, Nolato will hold a webcast conference call in English at 3:30 p.m. CET. Nolato will be represented by President and CEO Christer Wahlquist and CFO Per-Ola Holmström, who will present the yearend report and answer questions. Information regarding telephone numbers and the website is available at https://financialhearings.com/event/ 13234. The presentation will be available at www.nolato.com/ir after publication of the year-end report. The webcast will be available at the same address after the live broadcast.

Dividend

At the Annual General Meeting, the Board of Directors and the President and CEO will propose a dividend of SEK 1.90 per share (1.60), which corresponds to SEK 512 million (428). The pay-out ratio is 51% (53), excluding non-recurring items. The dividend yield was 1.8% on the share price as of December 31, 2021. Nolato's dividend policy is to propose a dividend that exceeds 50% of profit after tax, taking account of Nolato's long-term development opportunities, financial position and investment needs.

Ownership and legal structure

Nolato AB (publ), Swedish corporate identity number 556080-4592, is the Parent Company of the Nolato Group.

Nolato's Class B shares are listed on Nasdaq Stockholm in the Large Cap segment, where they are included in the Industrials sector.

There were 15,489 shareholders as of December 31. The largest shareholders are the Jorlén family and the Boström family with 9% each, the Hamrin family with 8%, and Capital Group and Lannebo Funds with 7% of capital each.

The Parent Company

For the parent company, which has no operating activities, sales amounted to SEK 69 million (69). Profit after financial income and expense was SEK 687 million (508).

Contingent liabilities totaled SEK 293 million (304).

Accounting and valuation principles

Nolato's consolidated accounts have been prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the EU.

The interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and applicable provisions of the Swedish Annual Accounts Act. Publication of this interim report is subject to the Swedish Securities Market Act.

The consolidated accounts have been prepared according to the same principles as in the most recent annual accounts, as set out in the Annual Report 2020.

IASB and the IFRS Interpretations Committee have issued new standards and statements that apply to financial years starting January 1, 2021, or later. There are no plans for the early application of new or amended standards for future application. None of the standards or interpretations published by IASB are expected to have a material impact on the Group or Parent Company's financial statements.

The interim report for the Parent Company has been prepared in accordance with Chapter 9 of the Swedish Annual Accounts Act.

Prior to publication this information constituted inside information that Nolato AB is obliged to publish pursuant to the EU Market Abuse Regulation. The information was issued for publication by the above contact persons on February 7, 2022 at 2.30 p.m. CET.

This report has not been audited by the company's auditors.

Annual General Meeting

The Annual General Meeting will be held on May 3, 2022. The Nomination Committee nominated Carina van den Berg for election to the Board and proposes the re-election of the other Board members and the Chairman of the Board. Shareholders who would like to submit proposals to the Nomination Committee can contact the chairman of the Nomination Committee, Henrik Jorlén, by email at [email protected] or by post at Kommendörsgatan 4, 269 77 Torekov, Sweden.

Financial information schedule

  • Three-month interim report 2022: 3 May 2022
  • 2022 Annual General Meeting: 3 May 2022
  • Six-month interim report 2022: 20 July 2022
  • Nine-month interim report 2022: 27 October 2022
  • 2022 year-end report: 8 February 2023

Torekov February 7, 2022 Nolato AB (publ) Nolato's Board of Directors

Nolato's business

Nolato is a global, advanced high-tech cooperation partner and manufacturer of polymer products and systems for leading customers in well-defined market areas such as medical technology, pharmaceuticals, consumer electronics, telecom, automotive, hygiene and other selected industrial sectors.

With its many years of experience, in-depth materials and processes expertise, early involvement in customer projects, advanced project management and detailed knowledge of each customer's specific requirements, Nolato is an effective and innovative partner.

Nolato's business model

Our business model is based on three decentralised business areas, which with their own decision-making and shared ambitions endeavour to fulfil our vision and financial targets.

The sharing of experience between our business areas, leading-edge technology, wide-ranging development and design know-how, advanced project management and efficient production allow us to establish long-term, innovative cooperation with our customers and partners and generate added value for both them and our shareholders.

Our shared values of being professional, well organised and responsible are reflected in everything we do.

Nolato's strategies

  • Early involvement in customers' development processes
  • Close and long-term collaboration/Partnerships with our customers
  • Innovative, integrated and high-tech solutions
  • High productivity/Lean manufacturing
  • Advancing up the value chain/Greater added value
  • Global presence
  • Responsible business practice

Nolato is a Swedish group with operations in Europe, Asia and North America.

We develop and manufacture products in polymer materials such as plastic, silicone and TPE for leading customers within medical technology, pharmaceuticals, consumer electronics, telecom, automotive, hygiene and other selected industrial sectors.

Nolato's shares are listed on Nasdaq Stockholm in the Large Cap segment, where they are included in the Industrials sector.

www.nolato.com

Q4 Q4 Full year Full year
SEK million Note 2021 2020 2021 2020
Net sales 1 3,146 2,487 11,610 9,359
Cost of goods sold – 2,678 – 2,069 – 9,793 – 7,853
Gross profit 468 418 1,817 1,506
Other operating income 15 2 70 29
Selling expenses – 47 – 43 – 178 – 138
Administrative expenses – 97 – 88 – 357 – 293
Other operating expenses – 13 – 15 – 19 – 56
– 142 – 144 – 484 – 458
Operating profit 2 326 274 1,333 1,048
Financial income and expense 2 107 – 5 68 – 34
Profit after financial income and expense 2 433 269 1,401 1,014
Tax – 47 – 58 – 241 – 208
Profit after tax 386 211 1,160 806
All earnings are attributable to the Parent Co.'s shareholders
Depreciation/amortization reg. non-current assets 123 115 472 408
Basic earnings per share, SEK 3 1.43 0.79 4.32 3.03
Diluted earnings per share, SEK 3 1.43 0.79 4.32 3.02
Number of shares at the end of the period, before dilution 269,377,080 267,442,080 269,377,080 267,442,080
Number of shares at the end of the period, after dilution 269,379,505 267,933,740 269,379,505 267,933,740
Average number of shares, before dilution 269,329,580 267,392,580 268,491,580 266,311,680
Average number of shares, after dilution 269,383,190 268,125,140 268,779,516 266,560,960

Consolidated income statement (summary)

At the end of the period, the Group had one incentive programme: Incentive Programme 2019/2024. For more information please see Note 3 Earnings per share on page 16.

Consolidated comprehensive income

Q4 Q4 Full year Full year
SEK million 2021 2020 2021 2020
Profit after tax 386 211 1,160 806
Other comprehensive income
Items that cannot be transferred to profit for the period
Revaluations of defined benefit pension plans 19 – 27 41 – 26
Tax attributable to items that cannot be transferred to profit for the period – 3 4 – 6 4
16 – 23 35 – 22
Items that have been converted or can be converted into profit for the period
Translation differences for the period on translation of foreign operations 78 – 143 195 – 139
Changes in the fair value of cash flow hedges for the period – 7 9 – 11
Tax attributable to changes in the fair value of cash flow hedges 1 – 2 2
78 – 149 202 – 148
Other comprehensive income, net of tax 94 – 172 237 – 170
Total comprehensive income for the period attributable to the Parent Co.'s shareh. 480 39 1,397 636

Financial instruments are measured at fair value in the statement of financial position, pursuant to measurement hierarchy Level 2.

Consolidated balance sheet (summary)

SEK million 31/12/2021 31/12/2020
Assets
Non-current assets
Intangible non-current assets 2,234 2,093
Property, plant and equipment 2,868 2,402
Non-current financial assets 2 2
Other non-current receivables 2 1
Deferred tax assets 69 50
Total fixed assets 5,175 4,548
Current assets
Inventories* 1,340 826
Accounts receivable 1,574 1,254
Other current assets2)* 518 367
Cash and bank 1,448 1,487
Total current assets* 4,880 3,934
Total assets* 10,055 8,482
Shareholders' equity and liabilities
Shareholders' equity 4,768 3,699
Long-term liabilities and provisions1) 1,921 1,584
Deferred tax liabilities1) 254 223
Current liabilities and provisions1) 3)* 3,112 2,976
Total liabilities and provisions* 5,287 4,783
Total shareholders' equity and liabilities* 10,055 8,482
1) Interest-bearing/non-interest-bearing liabilities and provisions:
Interest-bearing liabilities and provisions 2,041 2,417
Non-interest-bearing liabilities and provisions* 3,246 2,366
Total liabilities and provisions* 5,287 4,783

* As of December 31, 2020, inventories have been reclassified by SEK −284 million and other receivables by SEK +82 million, net SEK −202 million of total assets, which have since also reduced non-interest-bearing liabilities and provisions.

Financial instruments are measured at fair value in the statement of financial position,

pursuant to measurement hierarchy Level 2.

2) Derivative assets are included in other current assets at

3) Derivative liabilities are included in current liabilities and provisions at

1 27
5 18

Changes in consolidated shareholders' equity (summary)

Full year Full year
SEK million 2021 2020
Shareholders' equity at the beginning of the period 3,699 2,966
Total comprehensive income for the period 1,397 636
Dividends – 428
Share warrants included in incentive programmes 3 2
Exercise of warrants included in incentive programmes 97 95
Shareholders' equity at the end of period attributable to Parent Co's shareholders 4,768 3,699

At the end of the period, the Group had one incentive programme: Incentive Programme 2019/2024. In Incentive Programme 2019/2024, Series 2020/2023 has redemptions from 01/05/2023 to 15/12/2023 and Series 2021/2024 has redemptions from 01/05/2024 to 15/12/2024. The subscription price is SEK 92.88 for Series 2020/2023 and for Series 2021/2024 it is SEK 140.20. The programme has been taken into account in calculating the number of shares after dilution. Upon full subscription, the programme provide a maximum of 544,500 new class B shares.

Consolidated cash flow statement (summary)

Q4 Q4 Full year Full year
SEK million 2021 2020 2021 2020
Cash flow from operating activities before changes in working capital 313 501 1,402 1,057
Changes in working capital – 195 – 158 – 174 107
Cash flow from operating activities 118 343 1,228 1,164
Cash flow from investment activities – 205 – 102 – 782 – 1,695
Cash flow before financing activities – 87 241 446 – 531
Cash flow from financing activities 77 – 128 – 634 730
Cash flow for the period – 10 113 – 188 199
Cash and cash equivalents at the beginning of the period 1,400 1,438 1,487 1,362
Exchange rate difference in liquid assets 58 – 64 149 – 74
Cash and cash equivalents at the end of the period 1,448 1,487 1,448 1,487

Note 1 Revenue

Full year - 2021 Full year - 2020
Med. Integr. Indust. Med. Integr. Indust.
SEK million Sum Sol. Sol. Sol. Sum Sol. Sol. Sol.
Sweden 914 117 29 768 971 154 12 805
Other Europe 5,839 1,998 2,638 1,203 4,611 1,824 1,678 1,109
North America 2,083 1,668 154 261 1,225 853 152 220
Asia 2,588 153 2,352 83 2,390 122 2,204 64
Rest of world 193 131 53 9 165 136 22 7
Elimination internal sales – 7 – 3
Total revenues from customer contracts 11,610 4,067 5,226 2,324 9,359 3,089 4,068 2,205

The above table essentially covers products transferred at a specific date.

For the year 2021, the Group recognized increased provision of previously impaired trade receivables of SEK 11 million. Impairment losses are recognized in the cost of goods sold.

Note 2 Reconciliation of consolidated income before tax

Full year Full year
SEK million 2021 2020
Operating profit (EBIT)
Medical Solutions 430 391
Integrated Solutions 670 546
Industrial Solutions 200 163
Group adjustments, Parent Company 33 – 52
Consolidated operating profit (EBIT) 1,333 1,048
Financial income and expense (not distributed by business areas) 68 – 34
Consolidated profit before tax 1,401 1,014

Including a non-recurring item of SEK 50 million in operating profit for the full year 2021 and SEK 115 million in financial income and expense in Q4-2021 and full year 2021. The non-recurring items have been recognised at Group level and has therefore not affected the earnings of the business areas.

Including a non-recurring item of SEK −31 million in operating profit for full year 2020. The non-recurring item has been recognised at Group level and has therefore not affected the earnings of the business areas.

Note 3 Earnings per share (IFRS measures)

Q4 Q4 Full year Full year
SEK million 2021 2020 2021 2020
Profit after tax 386 211 1,160 806
Average number of shares, before dilution 269,329,580 267,392,580 268,491,580 266,311,680
Basic earnings per share (SEK) 1.43 0.79 4.32 3.03
Non-recurring items – 115 – 165 25
Profit after tax excluding non-recurring items 271 211 995 831
Basic earnings per share excluding non-recurring items (SEK) 1.01 0.79 3.71 3.12
Dilutive shares from Series 2017/2020 incentive programme with
exercise price SEK 48.51 per share; total 1,962,000 warrants 18,980 42,220
Dilutive shares from Series 2018/2021 incentive programme with
exercise price SEK 50.20 per share; total 1,935,000 warrants 23,540 713,580 287,451 207,060
Dilutive shares from Series 2020/2023 incentive programme with
exercise price SEK 92.88 per share; total 287,500 warrants 30,070 485
Average number of shares, after dilution 269,383,190 268,125,140 268,779,516 266,560,960
Diluted earnings per share (SEK) 1.43 0.79 4.32 3.02
Diluted earnings per share excluding non-recurring items (SEK) 1.01 0.79 3.70 3.12
Number of shares at the end of the period, before dilution 269,377,080 267,442,080 269,377,080 267,442,080
Number of shares at the end of the period, after dilution 269,379,505 267,933,740 269,379,505 267,933,740

At the end of the period, the Group had one incentive programme: Incentive Programme 2019/2024. In Incentive Programme 2019/2024, Series 2020/2023 has redemptions from 01/05/2023 to 15/12/2023 and Series 2021/2024 has redemptions from 01/05/2024 to 15/12/2024. The subscription price is SEK 92.88 for Series 2020/2023 and for Series 2021/2024 it is SEK 140.20. The programme has been taken into account in calculating the number of shares after dilution. Upon full subscription, the programme provide a maximum of 544,500 new class B shares.

Adjusted earnings per share (alternative performance measures)

Q4 Q4 Full year Full year
SEK million 2021 2020 2021 2020
Profit after tax 386 211 1,160 806
Adjusted earnings:
Amortization of intangible assets arising from acquisitions 10 9 36 18
Tax on amortization – 2 – 2 – 7 – 4
Adjusted earnings 394 218 1,189 820
Average number of shares, before dilution 269,329,580 267,392,580 268,491,580 266,311,680
Adjusted basic earnings per share (SEK) 1.46 0.82 4.43 3.08
Non-recurring items – 115 – 165 25
Adjusted earnings after tax, excluding non-recurring items 279 218 1,024 845
Adjusted basic earnings per share excluding non-recurring items (SEK) 1.04 0.82 3.81 3.17
Average number of shares, after dilution 269,383,190 268,125,140 268,779,516 266,560,960
Adjusted diluted earnings per share (SEK) 1.46 0.81 4.42 3.08
Adjusted diluted earnings per share excluding non-recurring items (SEK) 1.04 0.81 3.81 3.17

Five-year overview

IFRS measures 2021 2020 2019 2018 2017
Operating profit (EBIT) (SEK million) 1,333 1,048 887 941 749
Basic earnings per share (SEK) 4.32 3.03 2.66 2.74 2.17
Diluted earnings per share (SEK) 4.32 3.02 2.66 2.74 2.17
Alternative performance measures
Net sales (SEK million) 11,610 9,359 7,919 8,102 6,720
Operating profit (EBITA) (SEK million) 1,369 1,066 895 949 763
EBITA margin (%) 11.8 11.4 11.3 11.7 11.4
Profit after financial income and expense (SEK million) 1,401 1,014 857 921 731
Profit after tax (SEK million) 1,160 806 703 722 572
Cash flow after investments, excl. acq. and disposals (SEK million) 446 905 800 593 496
Cash conversion (%) 35 87 88 60 66
Return on capital employed (%) 22.8 20.7 23.1 29.7 26.6
Return on shareholders' equity (%) 28.0 23.9 25.5 30.4 29.4
Net financial liabilities (–) / assets (+), excl. pension- & lease
liabilities (SEK million)
– 51 – 298 666 341 31
Equity/assets ratio (%) 47 43 48 50 45
Adjusted basic earnings per share (SEK) 4.43 3.08 2.68 2.77 2.22
Adjusted diluted earnings per share (SEK) 4.42 3.08 2.68 2.76 2.22
Dividend per share (2021 proposal) (SEK) 1.90 1.60 1.40 1.25
Average number of employees 8,669 6,721 5,941 6,449 7,249

Including any non-recurring items.

Quarterly data (summary)

IFRS measures Note Q1 Q2 Q3 Q4 Full year
Operating profit (EBIT) (SEK million) 2 2021 299 377 331 326 1,333
2 2020 225 267 282 274 1,048
2019 173 232 236 246 887
Basic earnings per share (SEK) 3 2021 0.85 1.09 0.96 1.43 4.32
3 2020 0.67 0.78 0.79 0.79 3.03
2019 0.50 0.68 0.70 0.78 2.66
Diluted earnings per share (SEK) 3 2021 0.84 1.08 0.95 1.43 4.32
3 2020 0.67 0.78 0.79 0.79 3.02
2019 0.50 0.68 0.70 0.78 2.66
Alternative performance measures Note Q1 Q2 Q3 Q4 Full year
Net sales (SEK million) 1 2021 2,645 2,786 3,033 3,146 11,610
1 2020 2,065 2,307 2,500 2,487 9,359
2019 1,656 1,987 1,980 2,296 7,919
Operating profit (EBITDA) (SEK million) 2021 414 492 450 449 1,805
2020 319 360 388 389 1,456
2019 259 321 326 357 1,263
Operating profit (EBITA) (SEK million) 2021 308 386 339 336 1,369
2020 227 269 287 283 1,066
2019 175 233 238 249 895
EBITA margin (%) 2021 11.6 13.9 11.2 10.7 11.8
2020 11.0 11.7 11.5 11.4 11.4
2019 10.6 11.7 12.0 10.8 11.3
Profit after financial income and exp. (SEK million) 2 2021 286 360 322 433 1,401
2 2020 221 257 267 269 1,014
2019 166 223 232 236 857
Profit after tax (SEK million) 2021 226 291 257 386 1,160
2020 177 207 211 211 806
2019 131 180 186 206 703
Cash flow from operating activities (SEK million) 2021 249 500 361 118 1,228
2020 – 3 748 76 343 1,164
2019 130 265 83 682 1,160
Cash fl. from operations per share bef. dilution (SEK) 2021 0.93 1.86 1.34 0.44 4.58
2020 – 0.01 2.82 0.29 1.28 4.37
2019 0.49 1.00 0.31 2.57 4.38
Cash flow after investments, excluding acquisitions 2021 71 346 116 – 87 446
and disposals (SEK million) 2020 – 73 685 82 211 905
2019 25 178 – 4 601 800
Cash flow after investments, excl. acquisitions and 2021 0.27 1.29 0.43 – 0.32 1.66
disposals per share before dilution (SEK) 2020 – 0.27 2.58 0.31 0.79 3.40
2019 0.10 0.67 – 0.02 2.26 3.02
Adjusted basic earnings per share (SEK) 3 2021 0.87 1.11 0.98 1.46 4.43
3 2020 0.67 0.78 0.81 0.82 3.08
2019 0.51 0.68 0.71 0.78 2.68
Shareholders' equity per share, before dilution (SEK) 2021 15 15 16 18 18
2020 12 13 14 14 14
2019 11 10 11 11 11
Return on total capital (%) 2021 14.0 14.6 14.3 15.7 15.7
2020 15.7 15.8 14.8 14.3 14.3
2019 16.1 15.2 15.5 15.6 15.6
Alternative performance measures Q1 Q2 Q3 Q4 Full year
Return on capital employed (%) 2021 20.2 21.0 20.6 22.8 22.8
2020 23.2 23.4 21.8 20.7 20.7
2019 25.3 23.6 23.4 23.1 23.1
Return on operating capital (%) 2021 28.0 28.5 26.8 27.1 27.1
2020 31.2 33.1 30.9 29.2 29.2
2019 34.4 31.6 30.7 31.0 31.0
Return on shareholders' equity (%) 2021 23.8 25.1 25.1 28.0 28.0
2020 26.0 25.9 25.0 23.9 23.9
2019 25.9 24.5 24.7 25.5 25.5
Closing share price Nolato B (Nasdaq Stockholm) 2021 77.80 84.20 104.70 107.90 107.90
2020 44.94 62.80 87.30 83.20 83.20
2019 38.65 56.65 52.55 55.00 55.00

Including a non-recurring item of SEK 50 million in operating profit in Q2-2021 and SEK 115 million in profit after financial income and expense and profit after tax in Q4-2021, which in total impacted the profit after tax by SEK 165 million.

Including a non-recurring item of SEK −17 million in operating profit in Q3 2020 and tax effects of SEK +3 million, which impacted profit after tax by SEK −14 million.

Including a non-recurring item of SEK −14 million in operating profit in Q1 2020 and tax effects of SEK +3 million, which impacted profit after tax by SEK −11 million.

Including a non-recurring item of SEK −22 million in operating profit in Q4 2019 and tax effects of SEK +6 million, which impacted profit after tax by SEK −16 million.

Quarterly data business areas

Alternative performance measures
Net sales (SEK million) Note Q1 Q2 Q3 Q4 Full year
Medical Solutions 1 2021 1,006 1,021 977 1,063 4,067
1 2020 642 700 796 951 3,089
2019 611 634 612 627 2,484
Integrated Solutions 1 2021 1,045 1,186 1,519 1,476 5,226
1 2020 854 1,149 1,158 907 4,068
2019 512 821 862 1,097 3,292
Industrial Solutions 1 2021 595 580 540 609 2,324
1 2020 570 459 547 629 2,205
2019 533 541 512 573 2,159
Group adjustments, Parent Company 1 2021 – 1 – 1 – 3 – 2 – 7
1 2020 – 1 – 1 – 1 – 3
2019 – 9 – 6 – 1 – 16
Group total 1 2021 2,645 2,786 3,033 3,146 11,610
1 2020 2,065 2,307 2,500 2,487 9,359
2019 1,656 1,987 1,980 2,296 7,919
Alternative performance measures
Operating profit (EBITA) (SEK million) Q1 Q2 Q3 Q4 Full year
Medical Solutions 2021 121 124 100 112 457
EBITA margin (%) 12.0 12.1 10.2 10.5 11.2
2020 87 100 103 112 402
EBITA margin (%) 13.6 14.3 12.9 11.8 13.0
2019 78 82 80 80 320
EBITA margin (%) 12.8 12.9 13.1 12.8 12.9
Integrated Solutions 2021 125 154 200 192 671
EBITA margin (%) 12.0 13.0 13.2 13.0 12.8
2020 111 166 160 111 548
EBITA margin (%) 13.0 14.4 13.8 12.2 13.5
2019 57 107 116 147 427
EBITA margin (%) 11.1 13.0 13.5 13.4 13.0
Industrial Solutions 2021 66 62 42 38 208
EBITA margin (%) 11.1 10.7 7.8 6.2 9.0
2020 47 11 48 62 168
EBITA margin (%) 8.2 2.4 8.8 9.9 7.6
2019 44 46 44 47 181
EBITA margin (%) 8.3 8.5 8.6 8.2 8.4
Group adjustments, Parent Company 2021 – 4 46 – 3 – 6 33
2020 – 18 – 8 – 24 – 2 – 52
2019 – 4 – 2 – 2 – 25 – 33
Group total 2021 308 386 339 336 1,369
EBITA margin (%) 11.6 13.9 11.2 10.7 11.8
2020 227 269 287 283 1,066
EBITA margin (%) 11.0 11.7 11.5 11.4 11.4
2019 175 233 238 249 895
EBITA margin (%) 10.6 11.7 12.0 10.8 11.3

Including a non-recurring item of SEK 50 million in operating profit in Q2 2021. The non-recurring item has been recognized at Group level and has therefore not affected the earnings of the business areas.

Including a non-recurring item of SEK −17 million in operating profit in Q3 2020. The non-recurring item has been recognized at Group level and has therefore not affected the earnings of the business areas.

Including a non-recurring item of SEK −14 million in operating profit in Q1 2020. The non-recurring item has been recognized at Group level and has therefore not affected the earnings of the business areas.

Including a non-recurring item of SEK −22 million in operating profit in Q4 2019. The non-recurring item has been recognized at Group level and has therefore not affected the earnings of the business areas.

Depreciation/write-downs/amortization (SEK million) Q1 Q2 Q3 Q4 Full year
Medical Solutions 2021 61 61 63 64 249
2020 41 41 48 63 193
2019 39 40 40 41 160
Integrated Solutions 2021 15 16 15 16 62
2020 17 16 15 15 63
2019 17 17 16 16 66
Industrial Solutions 2021 39 38 41 42 160
2020 36 36 43 36 151
2019 30 32 34 35 131
Parent Company 2021 1 1
2020 1 1
2019 19 19
Group total 2021 115 115 119 123 472
2020 94 93 106 115 408
2019 86 89 90 111 376

Group financial highlights

Q4 Q4 Full year Full year
IFRS measures
Note
2021 2020 2021 2020
Basic earnings per share (SEK)
3
1.43 0.79 4.32 3.03
Diluted earnings per share (SEK)
3
1.43 0.79 4.32 3.02
Alternative performance measures
Net sales (SEK million)
1
3,146 2,487 11,610 9,359
Sales growth (%) 26 8 24 18
Percentage of sales outside Sweden (%) 93 89 92 90
Operating profit (EBITDA) (SEK million) 449 389 1,805 1,456
Operating profit (EBITA) (SEK million)1) 336 283 1,369 1,066
EBITA margin (%)1) 10.7 11.4 11.8 11.4
Profit after financial income and expense (SEK million)
2
433 269 1,401 1,014
Profit margin (%)1) 13.8 10.8 12.1 10.8
Profit after tax (SEK million) 386 211 1,160 806
Return on total capital (%)1) 15.7 14.3
Return on capital employed (%)1) 22.8 20.7
Return on operating capital (%)1) 27.1 29.2
Return on shareholders' equity (%)1) 28.0 23.9
Equity/assets ratio (%) 47 44
Debt/equity (%) 43 65
Interest coverage ratio (times) 49 28 34 28
Net investments affecting cash flow, excluding acquisitions and disposals
(SEK million)
205 102 782 347
Cash flow after investments, excluding acquisitions and disposals
(SEK million)
– 87 211 446 905
Cash conversion (%)1) 35 87
Net financial liabilities (–) / assets (+), excl. pension- & lease liab. (SEK million) – 51 – 298
Adjusted basic earnings per share (SEK)
3
1.46 0.82 4.43 3.08
Adjusted diluted earnings per share (SEK)
3
1.46 0.81 4.42 3.08
Cash flow from operations per share, before dilution (SEK) 0.44 1.28 4.58 4.37
Cash flow from operations per share, after dilution (SEK) 0.44 1.28 4.57 4.37
Cash flow after investments excluding acquisitions and disposals, per
share, before dilution (SEK)
– 0.32 0.79 1.66 3.40
Cash flow after investments excluding acquisitions and disposals, per
share, after dilution (SEK)
– 0.32 0.79 1.66 3.40
Shareholders' equity per share, before dilution (SEK) 18 14
Shareholders' equity per share, after dilution (SEK) 18 14
Average number of employees 8,669 6,721

1) KPIs calculated as specified on pages 23 and 24.

Including a non-recurring item of SEK 50 million in operating profit for the full year 2021 and SEK 115 million in profit after financial items in Q4-2021 and full year 2021, which in total impacted the profit after tax by SEK 165 million.

Including a non-recurring item of SEK −31 million in operating profit for full year 2020 and tax effects of SEK +6 million, which impacted profit after tax by SEK −25 million.

Definitions - IFRS measures

Earnings for the period that are attributable to the parent company's owners divided by the average number of outstanding shares.

Earnings per share Operating profit (EBIT)

Earnings before financial income and expense and taxes.

Definitions - Alternative performance measures

Nolato presents certain financial measures in this report that are not defined according to IFRS. Nolato considers that these measures provide valuable supplementary information for investors and company management, as they enable an assessment of trends and the company's performance. Since not all companies calculate financial measures in the same way, these are not always comparable to measures used by other companies. These financial measures should not therefore be regarded as substitutes for measures defined according to IFRS.

Adjusted earnings per share Interest coverage ratio

Profit after tax, excluding amortization of intangible assets arising from acquisitions, divided by the average number of shares.

Average number of shares

The average basic number of shares comprises the parent bearing assets. company's weighted average number of outstanding shares during the period. After dilution, a weighted average of the shares that may be issued under the ongoing share warrant programme is added, if they are in-the-money, but only insofar as the average listed share price for the period exceeds the subscription price of the warrants.

Cash conversion Profit margin

Cash flow after investments, excl. acquisitions and disposals, divided by operating profit (EBIT). Cash flow and operating profit have been adjusted by non-recurring items, if any.

Cash flow after investments, excl. acquisitions and disposals per share

Cash flow after investing activities excl. acquisitions and disposals, divided by the average number of shares.

Cash flow from operating activities per share Return on operating capital

Cash flow from operating activities, divided by the average number of shares.

Debt/equity ratio

Interest-bearing liabilities and provisions divided by

Equity/assets ratio

Shareholders' equity as a percentage of total capital in the balance sheet.

Profit after financial income and expense, plus financial expenses, divided by financial expenses.

Net financial liabilities (–) / financial assets (+)

Interest-bearing liabilities from credit institutions less interest-

Operating profit (EBITA)

Earnings before financial income and expense, taxes and amortization of intangible assets arising from acquisitions.

Operating profit (EBITDA)

Earnings before financial income and expense, taxes and depreciation/amortization.

Profit after financial income and expense as a percentage of net sales.

Return on capital employed

Profit after financial income and expense, plus financial expenses as a percentage of average capital employed. Capital employed consists of total capital less non-interest-bearing liabilities and provisions.

Return on shareholders' equity Operating profit as a percentage of average operating capital. Operating capital consists of total capital less non-interestbearing liabilities and provisions, less interest-bearing assets.

EBITA margin Return on total capital shareholders' equity. Profit after tax as a percentage of average shareholders' equity.

Operating profit (EBITA) as a percentage of net sales. Profit after financial income and expense, plus financial expenses as a percentage of average total capital in the balance sheet.

Forward-looking information

Some of the items reported relate to future events and actual outcomes may differ materially. In addition to those factors explicitly commented on, other factors may also materially affect the actual outcome, such as economic conditions, exchange rates and interest rate levels, political risks, competition and pricing, product development, commercialisation and technical difficulties, supply problems and customer credit losses.

Alternative performance measures

Q4 Q4 Full year Full year
SEK million unless otherwise specified Note 2021 2020 2021 2020
Operating profit (EBITDA) 449 389 1,805 1,456
Non-recurring items – 50 31
Adjusted operating profit (EBITDA) 449 389 1,755 1,487
Operating profit (EBIT) 2 326 274 1,333 1,048
Reversal of amortization of intangible assets arising in
connection with acquisitions 10 9 36 18
Operating profit (EBITA) 336 283 1,369 1,066
Non-recurring items – 50 31
Adjusted operating profit (EBITA) 336 283 1,319 1,097
EBITA margin (%) 10.7 11.4 11.8 11.4
Adjusted EBITA margin (%) 10.7 11.4 11.4 11.7
Profit after financial income and expense 2 433 269 1,401 1,014
Non-recurring items – 115 – 165 31
Adjusted profit after financial income and expense 318 269 1,236 1,045
Profit margin (%) 13.8 10.8 12.1 10.8
Adjusted profit margin (%) 10.1 10.8 10.6 11.2
Profit after tax 386 211 1,160 806
Non-recurring items – 115 – 165 31
Tax on non-recurring items – 6
Adjusted profit after tax 271 211 995 831
Cash flow after investments, excluding acquisitions and disposals 446 905
Non-recurring items (affecting cash flow) 36
Adjusted cash flow after investments, excl. acquisitions and disposals 446 941
Operating profit (EBIT) 2 1,333 1,048
Non-recurring items – 50 31
Adjusted operating profit (EBIT) 1,283 1,079
Cash conversion (%) 35 87

Including a non-recurring item of SEK 50 million in operating profit for the full year 2021 and SEK 115 million in profit after financial items in Q4-2021 and full year 2021, which in total impacted the profit after tax by SEK 165 million. The non-recurring items have been recognised at Group level and has therefore not affected the earnings of the business areas.

Including a non-recurring item of SEK −31 million in operating profit for full year 2020 and tax effects of SEK +6 million, which impacted profit after tax by SEK −25 million. The non-recurring item has been recognised at Group level and has therefore not affected the earnings of the business areas.

Alternative performance measures Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4
SEK million unless otherwise specified 2021 2021 2021 2021 2020 2020 2020 2020 2019
Profit after financial income and exp., rolling 12 months 1,401 1,238 1,183 1,078 1,015
Financial expense, rolling 12 months 43 44 44 41 38
Adj. profit after financial inc. and exp., rolling 12 months 1,444 1,282 1,227 1,119 1,053
Total capital, at the end of period 10,056 9,542 8,784 9,191 8,482 8,899 6,638 6,630 6,134
Average total capital, last 5 quarters 9,211 8,980 8,399 7,968 7,357
Return on total capital (%) 15.7 14.3 14.6 14.0 14.3
Adj. profit after financial inc. and exp., rolling 12 months 1,444 1,282 1,227 1,119 1,053
Capital employed, at the end of period 6,809 6,318 5,984 6,479 6,116 6,167 4,514 4,480 4,184
Average capital employed, last 5 quarters 6,341 6,213 5,852 5,551 5,092
Return on capital employed (%) 22.8 20.6 21.0 20.2 20.7
Operating profit (EBIT), rolling 12 months 1,333 1,281 1,232 1,122 1,048
Capital employed, at the end of period 6,809 6,318 5,984 6,479 6,116 6,167 4,514 4,480 4,184
Cash and bank, at the end of period – 1,448 – 1,400 – 1,248 – 1,563 – 1,487 – 1,438 – 1,906 – 1,333 – 1,362
Operating capital, at the end of period 5,361 4,918 4,736 4,916 4,629 4,729 2,608 3,147 2,822
Average operating capital, latest 5 quarters 4,912 4,786 4,324 4,006 3,587
Return on operating capital (%) 27.1 26.8 28.5 28.0 29.2
Profit after tax, rolling 12 months 1,160 985 939 855 806
Shareholders' equity, at the end of period 4,768 4,280 3,951 4,025 3,699 3,653 3,353 3,220 2,966
Average shareholders' equity, latest 5 quarters 4,145 3,922 3,736 3,590 3,378
Return on shareholders' equity (%) 28.0 25.1 25.1 23.8 23.9

Parent Company income statement (summary)

Q4 Q4 Full year Full year
SEK million 2021 2020 2021 2020
Net sales 16 20 69 69
Selling expenses – 3 – 2 – 8 – 6
Administrative expenses – 17 – 17 – 57 – 57
Other operating income 1 6 10 14
Other operating expenses – 10 – 10 – 38 – 40
Operating profit – 13 – 3 – 24 – 20
Profit from participations in Group companies 457 316 690 516
Financial income 20 18 74 32
Financial expenses – 34 13 – 53 – 20
Profit after financial income and expense 430 344 687 508
Appropriations 255 180 255 180
Tax – 89 – 59 – 80 – 53
Profit after tax 596 465 862 635
Depreciation/amortization 1 1

Parent Company balance sheet (summary)

SEK million 31/12/2021 31/12/2020
Assets
Property, plant and equipment 1 1
Financial assets 3,821 3,533
Total fixed assets 3,822 3,534
Other receivables 1,104 721
Cash and bank 60 477
Total current assets 1,164 1,198
Total assets 4,986 4,732
Shareholders' equity and liabilities
Shareholders' equity 3,107 2,572
Untaxed reserves 285 269
Deferred tax liabilities 17 9
Other provisions 6 7
Long-term liabilities 1,275 669
Current liabilities 296 1,206
Total shareholders' equity and liabilities 4,986 4,732
Transactions with related parties Period Services Services Interest Interest Result from Rec fr rel Liab to rel
sold bought income expenses shares in part on bal part on bal
SEK million Group com sheet date sheet date
Subsidiary Full year 2021 69 – 23 74 690 2,921 238
Subsidiary Full year 2020 69 – 24 32 516 2,255 382

None of the company's Board members or senior executives currently have, or have previously had, any direct or indirect involvement in any business transaction with the company which is, or was, of an unusual character in terms of its conditions. Nor has the Group issued any loans, pledged any guarantees or entered into any surety arrangements for any of the company's Board members or senior executives.

Nolato AB (publ), Nolatovägen 32, SE-269 78 Torekov, Sweden

• Tel. +46 431 442290 • Fax +46 431 442291

• Corp. id. number 556080-4592

• E-mail [email protected] • Website www.nolato.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.